Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma.
Matteo S. Carlino, MD, PhD, FRACP
Advertisement
Articles by Matteo S. Carlino, MD, PhD, FRACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?
2
FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
3
How Will Iberdomide’s Approval and Other CELMoDs Impact Multiple Myeloma?
4
Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?
5